Background: Prostate-specific antigen (PSA) is a widely used biochemical marker for the early detection and monitoring of patients with prostatic cancer.
Materials and Methods: This study was conducted on the patients of department of urology, S.P. Medical College and Associate group of Hospitals, Bikaner Fifty Six (56) Cases of Prostate enlargement benign, premalignant and malignant were included in this study. The selection of cases will be random.
Results: Maximum no. of patients of BPH was found in age group of 61-70 years (51.22%) and carcinoma found in 71-80 years age group (30.75%). The average age of BPH is found 67.29 years and average age of carcinoma is found 71.69 years. Maximum no. of patients (45 cases, 80.35%) presented with complaints of increased frequency of urine. Only one (7.70%) case out of 13 cases of adeno carcinoma was showing serum PSA level <4ng/ml.Only one (7.70%) case out of 13 cases of adeno carcinoma were showing serum PSA level 4-10ng/ml.11 (84.60%) case out of 13 cases of adeno carcinoma were showing serum PSA level >10ng/ml.14 (34.85%) cases out of 38 cases of BPH were showing serum PSA level of <4ng/ml.
Conclusion: In our study, PSA levels appear to be elevated in both benign and malignant lesions, therefore, the usefulness of PSA alone as an early detector of prostatic cancer by itself is questionable
Impact Factor
2022: 6.012
This work is licensed under a